Ziftomenib Patent Expiration

Ziftomenib was first introduced by Kura Oncology Inc in its drug Komzifti on Nov 13, 2025.

Ziftomenib Patents

Given below is the list of patents protecting Ziftomenib, along with the drug name that holds that patent and the company name owning that drug.

Filter patents by

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Komzifti	US12410184	Crystalline Forms Of A Menin Inhibitor	Jul 16, 2044	Kura
Komzifti	US12521396		Jul 16, 2044	Kura
Komzifti	US11944627	Methods For Treating Hematological Malignancies And Ewing'S Sarcoma	Sep 06, 2038	Kura
Komzifti	US10781218	Substituted Inhibitors Of Menin-Mll And Methods Of Use	Mar 15, 2037	Kura
Komzifti	US11673898	Substituted Inhibitors Of Menin-Mll And Methods Of Use	Mar 15, 2037	Kura
Komzifti	US10869868	Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression In Npm1 Mutant Leukemia	Jan 26, 2037	Kura
Komzifti	US10077271	Methods And Compositions For Inhibiting The Interaction Of Menin With Mll Proteins	Mar 16, 2036	Kura
Komzifti	US10174041	Methods And Compositions For Inhibiting The Interaction Of Menin With Mll Proteins	Mar 16, 2036	Kura

Drugs Generating Over $1 Billion in Annual Revenue

Explore the top-performing drugs that dominate the pharmaceutical industry

View List

NCE-1 Patent Expiry in the Next 1 Year

Identify opportunities as new chemical entity (NCE-1) patents approach expiry

View List

Recently Granted Patents in EP

Find the opportunity to file Oppositions

View List